As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining ...

Global Blood Therapeutics had developed Oxbryta that was used to treat haemolytic anaemia (excess breakdown of red blood cells) in patients aged 12 years and older who have sickle cell disease.

Sickle cell disease summit hosted by HHS highlights advancements and challenges. Learn about the summit and the experiences ...

Sickle cell patient files lawsuit against Global Blood Therapeutics, a wholly owned subsidiary of Pfizer, alleging harm from medication. The lawsuit, filed on Hardiman's behalf by the law firm ...

Newborn screening, comprehensive care, and disease-modifying therapies are changing the outlook for patients with sickle cell ...

The hemoglobin elevating agent is being developed for the treatment of anemia associated with multiple diseases.

Topline Data from 52-week Phase 3 Study Expected in Late 2025 –CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, ...

The "Sickle Cell Disease Market Assessment: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access" report has been added to ResearchAndMarkets.com's offering. The ...

Editas Medicine (EDIT) announced its achievement of in vivo preclinical proof of concept of hematopoietic stem and progenitor cell, HSPC, ...

Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET. Company Participants. Chris Taylor - Vice President, Investor Relations and ...